Sabby Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Sabby Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,073	Closed	-$317K	–	191
2018 Q1	$317K	Sell	1,073 -560	-34%	-$165K	0.04%	113
2017 Q4	$684K	Sell	1,633 -1,450	-47%	-$518K	0.06%	95
2017 Q3	$1.02M	Sell	3,083 -4,354	-59%	-$1.19M	0.07%	73
2017 Q2	$1.76M	Sell	7,437 -527	-7%	-$120K	0.12%	76
2017 Q1	$2.73M	Sell	7,964 -54	-0.7%	-$18.6K	0.15%	70
2016 Q4	$2.8M	Buy	8,018 +325	+4%	+$119K	0.16%	81
2016 Q3	$3.09M	Buy	7,693 +1,851	+32%	+$945K	0.12%	99
2016 Q2	$3.47M	Sell	5,842 -2,813	-33%	-$1.71M	0.18%	70
2016 Q1	$4.35M	Buy	+8,655	New	+$4.31M	0.22%	50
2014 Q4	–	Sell	-158	Closed	-$743	–	291
2014 Q3	$743	Buy	+158	New	+$835K	0.03%	168

Other funds holding EIGR

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management's EIGR Position: Q2 2018 in Review

Sabby Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2018, closing a stake of 1,073 shares — an estimated $317K sold.

Sabby Management first reported a position in EIGR in Q3 2014 and held it in 10 quarters. The position peaked at $4.35M in Q1 2016. 50 funds tracked by Wall St. Rank hold EIGR as of Q2 2018.

Sabby Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Sabby Management sold 1,073 Eiger BioPharmaceuticals, Inc. shares in Q2 2018, an estimated $317K.
Sabby Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2014 and held it in 10 quarters.
Sabby Management's Eiger BioPharmaceuticals, Inc. position peaked at $4.35M in Q1 2016.
50 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2018.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.